High Potency APIs /HPAPI Market

High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023

Report Code: PH 4897 Oct, 2019, by marketsandmarkets.com
Updated date -

[216 Pages Report] The global HPAPI market is expected to reach USD 26.84 Billion by 2023 from USD 16.49 Billion in 2017, at a CAGR 8.7%. The base year considered for the study is 2017 and the forecast period is from 2018 to 2023.

Market Dynamics

Increasing demand for oncology drugs

HPAPIs are extremely effective pharmacologically active ingredients. They are highly specific in their action and offer significant efficiency even at low daily therapeutic doses. HPAPIs have the ability to target precise disease cells and are, hence, used in formulations for highly potent drugs.

Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. According to the WHO, in 2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within 5 years of diagnosis) worldwide. The American cancer Society estimated that over 15.5 million American citizens were suffering from cancer as of January 2016, with over 1,688,780 new cancer cases expected to be diagnosed in 2017.

This growth in the number of cancer cases has a tremendous impact on the sales of cancer drugs across the globe. According to an article published in Nature Reviews, the pharmaceutical industrys 20 top-selling cancer drugs generate annual sales of over USD 50 billion worldwide, with Roche's Rituxan, Avastin, and Herceptin in the leading position generating USD 21 billion in sales.

Requirement of large investments

The cytotoxic nature of HPAPIs presents significant handling challenges and thus requires heavy investments for implementing specialized containment facilities that facilitate the safety of employees from exposure.

Although the HPAPIs market is an emerging and growing market, pharmaceutical manufacturers face significant challenges in upgrading their existing facilities that are capable of handling only low- or medium-potency APIs. Specialized containment to ensure protection of the employees and their environment from exposure accounts for a major cost. Contract manufacturers are required to heavily invest in building new facilities that are designed specifically for HPAPI manufacturing apart from the usual GMP production facilities; investments may sometimes amount to millions of dollars.

Manufacturers may also be required to invest in specialized facilities for HPAPI-antibody conjugations that incorporate both potent-compound handling and biologics processing capabilities. For instance, in October 2015, ADC Biotechnology (UK), invested USD 10 million to build a manufacturing facility for advanced anti-cancer drugs. These requirements of large investments is likely to restrain the growth of this market.

Opportunity in emerging markets

Emerging economies such as India, China, and the Middle East present high growth opportunities for players in the HPAPIs market. In most of these geographies, the market is expected to show a high growth rate in the coming years owing to their huge population, increasing prosperity, and improving longevity (albeit at differing rates).

Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries. According to the WHO, in 2014, nearly 66% of all cancer-related deaths occurred in developing countries. Additionally, according to GLOBOCAN 2012, a total of 6.8 million new cancer cases were reported in 2012 in Asia; this is expected to reach 8.4 million cases by 2020, indicating an increase of ~24%.

Furthermore, developing regions have lenient and flexible regulations, which make these markets highly lucrative for providers who are unable to meet the stringent standards set by the federal government in the US. Moreover, developing countries like India and China offer extremely low manufacturing and labor costs and highly skilled labor; this encourages players in developed regions to invest in this market.

Constant evolution of industry standards and technologies

One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations. Companies that are willing to enter this marker are required to adopt these newer technologies, which generally translates to huge investments. For example, SAFC (US) had to upgrade its HPAPI manufacturing facility in the US in 2016 to include more robust analytical technologies with improved sensitivity and detection levels that allow for the determination of potential API carryover at part-per-billion levels. Such a rapidly evolving environment poses a challenge to the players in this market.

The objectives of this study are as follows:

  • To define, describe, and forecast the global HPAPI market on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region
  • To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments of North America, Europe, Asia, and the Rest of the World (RoW)
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as agreements, partnerships, collaborations, and alliances; mergers and acquisitions; expansions; and R&D activities in the global market

Research Methodology

The study estimates the market size for 2018 and projects its demand till 2023. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side included hospitals, research institutes, and laboratories.

For the market estimation process, both top-down and bottom-up approaches were used to estimate and validate the market size of the HPAPI market as well as to estimate the market size of various other dependent submarkets. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Secondary sources such as directories, databases, white papers, annual reports, company house documents, investor presentations, and SEC filings of companies were referred to. Some of the secondary sources include Active Pharmaceutical Ingredients Committee (APIC), Chemical Pharmaceutical Generic Association (CPA), Swiss Biotech Association, International Pharmaceutical Congress Advisory Association (IPCAA), World Health Organization (WHO), American Cancer Society (ACS), American Association for Cancer Research (AACR), Canadian Cancer Society, and European Association for Cancer Research (EACR).

High Potency APIs Market-Breakdown of Primary Participants

To know about the assumptions considered for the study, download the pdf brochure

The HPAPI market is fragmented market with the presence of several small and big players. Prominent players in this market include Pfizer (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva (Israel), Eli Lilly and Company (US), Merck (US), AbbVie (US), Mylan (US), and F. Hoffmann-La Roche (Switzerland).

Target Audience for this Report:

  • Manufacturers of HPAPI
  • Distributors and suppliers of HPAPIs
  • Potential investors in the HPAPI market
  • Pharmaceutical companies
  • Biotechnology companies
  • Contract manufacturing organizations
  • Life science research centers
  • Healthcare payers

Scope of the Report

The research report categorizes the market into the following segments and subsegments:

Market, by Type

  • Innovative HPAPI
  • Generic HPAPI

Market, by Type of Manufacturer

  • Captive HPAPI Manufacturers
  • Merchant HPAPI Manufacturers
    • By Type
      • Innovative
      • Generic
    • By Type of Synthesis
      • Synthetic
      • Biotech

Market, by Type of Synthesis

  • Synthetic HPAPI Market
    • Synthetic HPAPI Market, by Type
      • Innovative Synthetic HPAPI
      • Generic Synthetic HPAPI
  • Biotech HPAPI Market
    • By Type
      • Innovative Biotech HPAPI
      • Biosimilars
    • By Product
      • Monoclonal Antibodies
      • Vaccines
      • Recombinant Proteins

Market, by Therapeutic Application

  • Oncology
  • Hormonal Disorders
  • Glaucoma
  • Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)

Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia
    • Japan
    • China
    • India
    • Rest of Asia (RoA)
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.

The following customization options are available for the report:

Additional Company Profiling

  • Company profiles for 5 additional companies.

The global HPAPI market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.

This report segments the market into type, type of manufacturer, type of synthesis, therapeutic application, and region. Based on type, the market is segmented into innovative and generic APIs. In 2018, the innovative HPAPIs segment is expected to account for the largest share of the market. The large share can be attributed to the increased investments of innovator companies in R&D, manufacture, marketing, and supply of innovative HPAPIs as the revenue generated from these molecules are considerably high.

On the basis of type of manufacturer, the market is segmented into captive HPAPI and merchant HPAPI manufacturers. In 2018, the captive HPAPI manufacturers segment is expected to account for the largest share of the market. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for economic benefits.

On the basis of type of synthesis, the market is categorized into synthetic and biotech HPAPIs. The synthetic HPAPI segment is expected to command the largest share in 2018. The increasing emergence of new molecules in the market, rising number of product approvals, technological advancements in synthesis, and ease of production are driving the growth of the synthetic HPAPI segment.

On the basis of therapeutic application, the market is segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is expected to account for the largest share of the global market in 2018. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this segment.

HPAPI Market-By Region 2023

Geographically, the HPAPI market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the market in 2018, followed by Europe. However, Asia is expected to grow at the highest CAGR during the forecast period. Factors such as growth in geriatric population, high prevalence of chronic and lifestyle diseases, increase in disposable income, prevalence of lifestyle- and age-related diseases, government efforts to reform healthcare and encourage the adoption of generics, and growing market for merchant manufacturers in this region owing to the low labor and manufacturing costs are driving the growth of the market in Asia.

While the market presents significant growth opportunities, market growth may be hindered factors like requirement of large investments, discrepancies in HPAPI banding systems, uncertainties associated with products and high risk of cross-contamination are the major factors.

The HPAPI Market is competitive in nature, with several major players competing for market space. Some of the prominent players in this market are Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan, Inc. (US), Boehringer Ingelheim (Germany), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Market: Introduction (Page No. - 21)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Study Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Market Stakeholders

2 Market: Research Methodology (Page No. - 24)
    2.1 Secondary Data
           2.1.1 Key Data From Secondary Sources
    2.2 Primary Data
           2.2.1 Key Data From Primaries
           2.2.2 Insights From Industry Experts
    2.3 Market Size Estimation
    2.4 Market Breakdown and Data Triangulation
    2.5 Assumptions for the Study

3 Market: Executive Summary (Page No. - 32)

4 Market: Premium Insights (Page No. - 37)
    4.1 High-Potency Active Pharmaceutical Ingredients Market: Overview
    4.2 Global Market, By Type, 2018 vs 2023 (USD Billion)
    4.3 Global Market, By Type of Synthesis, 2018 vs 2023 (USD Billion)
    4.4 Global Market, By Therapeutic Area (2018–2023)
    4.5 Geographical Snapshot of the Global Market

5 Market: Overview (Page No. - 41)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Demand for Oncology Drugs
                    5.2.1.2 Growing Demand for Antibody-Drug Conjugates
                    5.2.1.3 Increasing Focus of Leading Pharmaceutical Companies on HPAPI
                    5.2.1.4 Advancements in HPAPI Manufacturing Technologies
                    5.2.1.5 Growing Focus on Precision Medicine
           5.2.2 Restraints
                    5.2.2.1 Requirement of Large Investments
                    5.2.2.2 Discrepancies in HPAPI Banding Systems
                    5.2.2.3 Uncertainties Associated With Products
                    5.2.2.4 High Risk of Cross-Contamination
           5.2.3 Opportunities
                    5.2.3.1 Growing Opportunities for CMOS and CDMOS
                    5.2.3.2 Emerging Markets
           5.2.4 Challenges
                    5.2.4.1 Need for Appropriate Process Designs
                    5.2.4.2 Constant Evolution of Industry Standards and Technologies

6 High-Potency Active Pharmaceutical Ingredients Classification and Overview (Page No. - 49)
    6.1 Introduction
    6.2 High-Potency Active Pharmaceutical Ingredients Classification as Per Safebridge Consultants

7 Market, By Type (Page No. - 52)
    7.1 Introduction
    7.2 Innovative High-Potency Active Pharmaceutical Ingredients
    7.3 Generic High-Potency Active Pharmaceutical Ingredients

8 Market, By Type of Synthesis (Page No. - 60)
    8.1 Introduction
    8.2 Synthetic High-Potency Active Pharmaceutical Ingredients
           8.2.1 Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type
                    8.2.1.1 Innovative Synthetic HPAPI
                    8.2.1.2 Generic Synthetic HPAPI
    8.3 Biotech High-Potency Active Pharmaceutical Ingredients
           8.3.1 Biotech High-Potency Active Pharmaceutical Ingredients Market, By Type
                    8.3.1.1 Innovative Biotech HPAPI
                    8.3.1.2 Biosimilars
           8.3.2 Biotech High-Potency Active Pharmaceutical Ingredients Market, By Product
                    8.3.2.1 Monoclonal Antibodies
                    8.3.2.2 Vaccines
                    8.3.2.3 Recombinant Proteins

9 Market, By Type of Manufacturer (Page No. - 79)
    9.1 Introduction
    9.2 Captive HPAPI Manufacturers
    9.3 Merchant HPAPI Manufacturers
           9.3.1 Merchant HPAPI Manufacturers Market, By Type
                    9.3.1.1 Innovative Merchant HPAPI Manufacturers
                    9.3.1.2 Generic Merchant HPAPI Manufacturers
           9.3.2 Merchant HPAPI Manufacturers Market, By Type of Synthesis
                    9.3.2.1 Synthetic HPAPIs
                    9.3.2.2 Biotech HPAPIs

10 Market, By Therapeutic Application (Page No. - 97)
     10.1 Introduction
     10.2 Oncology
     10.3 Hormonal Imbalance
     10.4 Glaucoma
     10.5 Other Therapeutic Applications

11 Market, By Region (Page No. - 108)
     11.1 Introduction
     11.2 North America
             11.2.1 US
             11.2.2 Canada
     11.3 Europe
             11.3.1 Germany
             11.3.2 France
             11.3.3 UK
             11.3.4 Italy
             11.3.5 Spain
             11.3.6 Rest of Europe (RoE)
     11.4 Asia
             11.4.1 Japan
             11.4.2 China
             11.4.3 India
             11.4.4 Rest of Asia (RoA)
     11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. - 177)
     12.1 Overview
     12.2 Market Ranking Analysis
     12.3 Competitive Situation and Trends
             12.3.1 Agreements, Collaborations, and Partnerships
             12.3.2 Mergers and Acquisitions
             12.3.3 Expansions

13 Company Profiles (Page No. - 183)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     13.1 Pfizer
     13.2 Novartis International AG
     13.3 Sanofi
     13.4 F. Hoffmann-La Roche
     13.5 Bristol-Myers Squibb
     13.6 Boehringer Ingelheim
     13.7 Teva Pharmaceutical Industries
     13.8 ELI Lilly and Company
     13.9 Merck
     13.10 Abbvie
     13.11 Mylan
     13.12 Bayer

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. - 208)
     14.1 Insights From Industry Experts
     14.2 Discussion Guide
     14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     14.4 Introducing RT: Real-Time Market Intelligence
     14.5 Available Customizations
     14.6 Related Reports
     14.7 Author Details


List of Tables (239 Tables)

Table 1 Pipeline of Oncology Drugs (2018)
Table 2 Therapeutic Monoclonal Antibodies Approved By the Fda in 2016
Table 3 Market, By Type, 2016–2023 (USD Million)
Table 4 Innovative HPAPI Market, By Region, 2016–2023 (USD Million)
Table 5 North America: Innovative HPAPI Market, By Country, 2016–2023 (USD Million)
Table 6 Europe: Innovative HPAPI Market, By Country, 2016–2023 (USD Million)
Table 7 Asia: Innovative HPAPI Market, By Country, 2016–2023 (USD Million)
Table 8 Generic High-Potency Active Pharmaceutical Ingredients Market, By Region, 2016–2023 (USD Million)
Table 9 North America: Generic High-Potency Active Pharmaceutical Ingredients Market, By Country, 2016–2023 (USD Million)
Table 10 Europe: Generic HPAPI Market, By Country, 2016–2023 (USD Million)
Table 11 Asia: Generic HPAPI Market, By Country, 2016–2023 (USD Million)
Table 12 Market, By Type of Synthesis, 2016- 2023 (USD Million)
Table 13 Synthetic HPAPI Market, By Region, 2016- 2023 (USD Million)
Table 14 North America: Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 15 Europe: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Country, 2016- 2023 (USD Million)
Table 16 Asia: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Country, 2016- 2023 (USD Million)
Table 17 Synthetic HPAPI Market, By Type, 2015-2022 (USD Million)
Table 18 Innovative Synthetic HPAPI Market, By Region, 2016- 2023 (USD Million)
Table 19 North America: Innovative Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 20 Europe: Innovative Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 21 Asia: Innovative Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 22 Generic Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Region, 2016- 2023 (USD Million)
Table 23 North America: Generic Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 24 Europe: Generic Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 25 Asia: Generic Synthetic HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 26 Biotech HPAPI Market, By Region, 2016- 2023 (USD Million)
Table 27 North America: Biotech HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 28 Europe: Biotech HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 29 Asia: Biotech HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 30 Biotech HPAPI Market, By Type, 2016- 2023 (USD Million)
Table 31 Innovative Biotech High-Potency Active Pharmaceutical Ingredients Market, By Region, 2016- 2023 (USD Million)
Table 32 North America: Innovative Biotech HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 33 Europe: Innovative Biotech HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 34 Asia: Innovative Biotech HPAPI Market, By Country, 2016- 2023 (USD Million)
Table 35 Biosimilars Market, By Region, 2016- 2023 (USD Million)
Table 36 North America: Biosimilars Market, By Country, 2016- 2023 (USD Million)
Table 37 Europe: Biosimilars Market, By Country, 2016- 2023 (USD Million)
Table 38 Asia: Biosimilars Ingredients Market, By Country, 2016- 2023 (USD Million)
Table 39 Biotech High-Potency Active Pharmaceutical Ingredients Market, By Product, 2016- 2023 (USD Million)
Table 40 Monoclonal Antibodies Market, By Region, 2016- 2023 (USD Million)
Table 41 Vaccines Market, By Region, 2016- 2023 (USD Million)
Table 42 Recombinant Proteins Market, By Region, 2016- 2023 (USD Million)
Table 43 Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 44 Captive HPAPI Manufacturers Market, By Region, 2016–2023 (USD Million)
Table 45 North America: Captive HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 46 Europe: Captive HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 47 Asia: Captive HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 48 Merchant HPAPI Manufacturers Market, By Region, 2016–2023 (USD Million)
Table 49 North America: Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 50 Europe: Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 51 Asia: Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 52 Global Merchant HPAPI Manufacturers Market, By Type, 2016-2023, (USD Million)
Table 53 Innovative Merchant HPAPI Manufacturers Market, By Region, 2016–2023 (USD Million)
Table 54 North America: Innovative Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 55 Europe: Innovative Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 56 Asia: Innovative Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 57 Generic Merchant HPAPI Manufacturers Market, By Region, 2016–2023 (USD Million)
Table 58 North America: Generic Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 59 Europe: Generic Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 60 Asia: Generic Merchant HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 61 Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016-2023, (USD Million)
Table 62 Merchant Synthetic HPAPI Manufacturers Market, By Region, 2016–2023 (USD Million)
Table 63 North America: Merchant Synthetic HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 64 Europe: Merchant Synthetic HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 65 Asia: Merchant Synthetic HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 66 Merchant Biotech HPAPI Manufacturers Market, By Region, 2016–2023 (USD Million)
Table 67 North America: Merchant Biotech HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 68 Europe: Merchant Biotech HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 69 Asia: Merchant Biotech HPAPI Manufacturers Market, By Country, 2016–2023 (USD Million)
Table 70 Global Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 71 High-Potency Active Pharmaceutical Ingredients Market for Oncology, By Region, 2016–2023 (USD Million)
Table 72 North America: Market for Oncology, By Country, 2016–2023 (USD Million)
Table 73 Europe: Market for Oncology, By Country, 2016–2023 (USD Million)
Table 74 Asia: Market for Oncology, By Country, 2016–2023 (USD Million)
Table 75 Market for Hormonal Imbalance, By Region, 2016–2023 (USD Million)
Table 76 North America: Market for Hormonal Imbalance, By Country, 2016–2023 (USD Million)
Table 77 Europe: Market for Hormonal Imbalance, By Country, 2016–2023 (USD Million)
Table 78 Asia: Market for Hormonal Imbalance, By Country, 2016–2023 (USD Million)
Table 79 High-Potency Active Pharmaceutical Ingredients Market for Glaucoma, By Region, 2016–2023 (USD Million)
Table 80 North America: Market for Glaucoma, By Country, 2016–2023 (USD Million)
Table 81 Europe: Market for Glaucoma, By Country, 2016–2023 (USD Million)
Table 82 Asia: Market for Glaucoma, By Country, 2016–2023 (USD Million)
Table 83 Market for Other Therapeutic Applications, By Region, 2016–2023 (USD Million)
Table 84 North America: Market for Other Therapeutic Applications, By Country, 2016–2023 (USD Million)
Table 85 Europe: Market for Other Therapeutic Applications, By Country, 2016–2023 (USD Million)
Table 86 Asia: Market for Other Therapeutic Applications, By Country, 2016–2023 (USD Million)
Table 87 Market, By Region, 2016–2023 (USD Million)
Table 88 North America: Market, By Country, 2016–2023 (USD Million)
Table 89 North America: Market, By Type, 2016–2023 (USD Million)
Table 90 North America: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 91 North America: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 92 North America: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 93 North America: High-Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 94 North America: Synthetic HPAPI Market, By Type, 2016–2023 (USD Million)
Table 95 North America: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 96 North America: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 97 North America: HPAPI Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 98 US: High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 99 US: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 100 US: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 101 US: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 102 US: High-Potency API Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 103 US: Synthetic High-Potency API Market, By Type, 2016–2023 (USD Million)
Table 104 US: Biotech High-Potency API Market, By Type, 2016–2023 (USD Million
Table 105 US: Biotech High-Potency API Market, By Product, 2016–2023 (USD Million)
Table 106 US: High-Potency API Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 107 Canada: Market, By Type, 2016–2023 (USD Million)
Table 108 Canada: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 109 Canada: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 110 Canada: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 111 Canada: High-Potency API Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 112 Canada: Synthetic High-Potency API Market, By Type, 2016–2023 (USD Million)
Table 113 Canada: Biotech High-Potency API Market, By Type, 2016–2023 (USD Million)
Table 114 Canada: Biotech High-Potency API Market, By Product, 2016–2023 (USD Million)
Table 115 Canada: High-Potency API Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 116 Europe: High-Potency Active Pharmaceutical Ingredients Market, By Country, 2016–2023 (USD Million)
Table 117 Europe: Market, By Type, 2016–2023 (USD Million)
Table 118 Europe: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 119 Europe: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 120 Europe: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 121 Europe: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 122 Europe: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 123 Europe: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 124 Europe: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 125 Europe: High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 126 Germany: Market, By Type, 2016–2023 (USD Million)
Table 127 Germany: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 128 Germany: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 129 Germany: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 130 Germany: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 131 Germany: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 132 Germany: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 133 Germany: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 134 Germany: High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 135 France: Market, By Type, 2016–2023 (USD Million)
Table 136 France: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 137 France: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 138 France: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 139 France: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 140 France: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 141 France: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 142 France: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 143 France: High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 144 UK: Market, By Type, 2016–2023 (USD Million)
Table 145 UK: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 146 UK: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 147 UK: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 148 UK: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 149 UK: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 150 UK: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 151 UK: Biotech High-Potency Active Pharmaceutical Ingredients Market, By Product, 2016–2023 (USD Million)
Table 152 UK: Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 153 Italy: Market, By Type, 2016–2023 (USD Million)
Table 154 Italy: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 155 Italy: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 156 Italy: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 157 Italy: High-Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 158 Italy: Synthetic HPAPI Market, By Type, 2016–2023 (USD Million)
Table 159 Italy: Biotech High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 160 Italy: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 161 Italy: High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 162 Spain: High-Potency API Market, By Type, 2016–2023 (USD Million)
Table 163 Spain: High-Potency API Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 164 Spain: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 165 Spain: Merchant Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 166 Spain: High-Potency API Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 167 Spain: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 168 Spain: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 169 Spain: Biotech High-Potency Active Pharmaceutical Ingredients Market, By Product, 2016–2023 (USD Million)
Table 170 Spain: High-Potency API Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 171 RoE: High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 172 RoE: High-Potency API Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 173 RoE: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 174 RoE: Merchant Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 175 RoE: High-Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 176 RoE: Synthetic High-Potency API Market, By Type, 2016–2023 (USD Million)
Table 177 RoE: Biotech High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 178 RoE: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 179 RoE: High-Potency API Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 180 Asia: High-Potency Active Pharmaceutical Ingredients Market, By Country, 2016–2023 (USD Million)
Table 181 Asia: Market, By Type, 2016–2023 (USD Million)
Table 182 Asia: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 183 Asia: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 184 Asia: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 185 Asia: High-Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 186 Asia: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 187 Asia: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 188 Asia: Biotech High-Potency Active Pharmaceutical Ingredients Market, By Product, 2016–2023 (USD Million)
Table 189 Asia: Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 190 Japan: High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 191 Japan: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 192 Japan: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 193 Japan: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 194 Japan: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 195 Japan: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 196 Japan: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 197 Japan: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 198 Japan: Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 199 China: Market, By Type, 2016–2023 (USD Million)
Table 200 China: High-Potency Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 201 China: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 202 China: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 203 China: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 204 China: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 205 China: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 206 China: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 207 China: Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 208 India: High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 209 India: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 210 India: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 211 India: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 212 India: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 213 India: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 214 India: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 215 India: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 216 India: Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 217 RoA: High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 218 RoA: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 219 RoA: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 220 RoA: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 221 RoA: Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 222 RoA: Synthetic High-Potency Active Pharmaceutical Ingredients Market, By Type, 2016–2023 (USD Million)
Table 223 RoA: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 224 RoA: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 225 RoA: High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 226 RoW: Market, By Type, 2016–2023 (USD Million)
Table 227 RoW: Market, By Type of Manufacturer, 2016–2023 (USD Million)
Table 228 RoW: Merchant HPAPI Manufacturers Market, By Type, 2016–2023 (USD Million)
Table 229 RoW: Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 230 RoW: High-Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2016–2023 (USD Million)
Table 231 RoW: Synthetic HPAPI Market, By Type, 2016–2023 (USD Million)
Table 232 RoW: Biotech HPAPI Market, By Type, 2016–2023 (USD Million)
Table 233 RoW: Biotech HPAPI Market, By Product, 2016–2023 (USD Million)
Table 234 RoW: High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application, 2016–2023 (USD Million)
Table 235 Market Ranking Analysis, By Key Player, 2017
Table 236 Agreements, Collaborations, Partnerships, and Alliances (2015–2018)
Table 237 Mergers and Acquisitions (2015-2018)
Table 238 Expansions (2015–2018)
Table 239 Exchange Rates (Utilized for the Conversion of Chf to USD)


List of Figures (42 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation: Bottom-Up Approach
Figure 4 Market Size Estimation: Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 High-Potency Active Pharmaceutical Ingredients Market, By Type, 2018 vs 2023
Figure 7 Market, By Type of Manufacturer, 2018 vs 2023
Figure 8 Market, By Type of Synthesis, 2018 vs 2023
Figure 9 Market, By Therapeutic Application, 2018 vs 2023
Figure 10 Geographic Snapshot of the High-Potency Active Pharmaceutical Ingredients Market (2018–2023)
Figure 11 Increasing Demand for Oncology Drugs & Antibody-Drug Conjugates—Major Factor Driving Market Growth During the Forecast Period
Figure 12 Innovative HPAPIs Will Continue to Dominate the Global Market in 2023
Figure 13 Synthetic HPAPIs to Account for the Largest Market Share in 2018
Figure 14 Oncology Segment to Register the Highest CAGR During the Forecast Period
Figure 15 China & India to Register High Growth Rates During 2018–2023
Figure 16 High-Potency Active Pharmaceutical Ingredients Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Market, By Type
Figure 18 Innovative HPAPIs Segment to Dominate the High-Potency Active Pharmaceutical Ingredients Market in 2018
Figure 19 Synthetic Segment to Dominate the Market in 2018
Figure 20 Captive HPAPI Manufacturers Segment is Expected to Account for Largest Share of the Market in 2018
Figure 21 North America to Dominate the Captive HPAPI Manufacturers Market in 2018
Figure 22 Oncology Segment to Dominate the High-Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application (2018)
Figure 23 Asia to Witness the Highest Growth Rate During the Forecast Period (2018–2023)
Figure 24 North America: Market Snapshot (2018)
Figure 25 Europe: Market Snapshot
Figure 26 Asia: HPAPI Market Snapshot
Figure 27 Rest of the World: Market Snapshot
Figure 28 Key Developments in the Market, 2015–2018
Figure 29 Market Evolution Framework— Agreements, Collaborations, Partnerships, and Alliances Fueled Market Growth
Figure 30 Battle for Market Share: Agreements, Collaborations, and Partnerships Was the Key Strategy Adopted By Market Players (2015–2018)
Figure 31 Pfizer: Company Snapshot (2016)
Figure 32 Novartis International AG: Company Snapshot (2016)
Figure 33 Sanofi: Company Snapshot (2017)
Figure 34 F. Hoffmann-La Roche: Company Snapshot (2017)
Figure 35 Bristol-Myers Squibb: Company Snapshot (2016)
Figure 36 Boehringer Ingelheim: Company Snapshot (2016)
Figure 37 Teva Pharmaceutical Industries: Company Snapshot (2017)
Figure 38 ELI Lilly and Company: Company Snapshot (2016)
Figure 39 Merck: Company Snapshot (2016)
Figure 40 Abbvie: Company Snapshot (2017)
Figure 41 Mylan: Company Snapshot (2017)
Figure 42 Bayer: Company Snapshot (2017)


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
PH 4897
Published ON
Oct, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the High Potency APIs /HPAPI Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home